Circulating Tumor Cells Market Analysis By Technology (Enrichment, Detection, Analysis, Ex-vivo & In-vivo Positive Selection, Negative Selection, Microchips, Single Spiral Micro channel, Immunocytochemical, Molecular RNA Based, EPISPOT In-vitro Cell Culture, In-vitro Cell Invasion Assay, & Xenotransplantation Technologies), By Application (EMT Biomarkers Development, Tumorigenesis, & Cancer Stem Cell Research), And Segment Forecasts To 2022

Published: Jan, 2016 | Pages: 84 | Publisher: Grand View Research
Industry: Biotechnology | Report Format: Electronic (PDF)

Global circulating tumor cells market is anticipated to reach USD 11,552.3 million by 2022, according to a new report by Grand View Research, Inc. Rising developments in the field of biomedical engineering and biomedical imaging coupled with rise in patented research initiatives by the government is expected to drive this industry through the forecast period. 

Introduction of novel technologies for enumeration of circulating tumor cells is anticipated to fuel growth in this sector through to 2022. Furthermore, increasing incidences of chronic oncology diseases that depend on the detection and analysis of CTCs, as it has enormous potential in the  real-time monitoring of cancer therapy, over the conventional methods such as imaging technologies and tumor tissue biopsy. 

Additionally, application of CTC as biomarkers for drug discovery is a promising factor for growth in the coming years. Utilization of the circulating tumor cells in development of tumor specific biomarkers in order to optimize the selection of targeted therapies and assessment of better response to the therapy is expected to support in the projected growth of CTC market in the coming years. 

Further key findings from the study suggest:

CTC enrichment accounted for the largest share of market revenue in 2014 and is expected to continue this dominance owing to high usage rates in oncology research establishments and high accuracy exhibited by this technology. 

Microchips technology is anticipated to register substantial growth in the next seven years because of the introduction of cluster chip technology that enables capture of clusters of tumor cells for CTC quantitation. 

Characteristic property of the cancer stem cells of self-renewal in replenishing the growing cancer is driving the attention of organizations and researchers in CTC cancer stem cell research segment thus accounting for the segment's large share in revenue generation. 

Application of alterations witnessed in the expression profiles of EMT-associated transcriptional regulators and their molecular targets as biomarkers in EMT study is expected to serve as an impetus for diagnosis of tumour recurrence consequently driving the segment with a double digit CAGR of over 10%. 

North America dominated the market in 2014, with revenue estimation that accounted for over 45% of the global market. Presence of strong oncology research funding, refined healthcare infrastructure, growing incidence of cancer, favorable government initiatives with respect to R&D funding for clinical diagnostic products are factors attributive for larger revenue share. 

Asia Pacific is anticipated to witness lucrative CAGR of over 16% as a result of infrastructure development in care centers coupled with increase in sales of CTC diagnostic tests. The need of new diagnosis methods for the growing cancer cases has gushed up research on new developments in developing economies of this region thus providing potential avenues for market growth. 

Key participants of CTC industry include Canopus Biosciences, Clearbridge BioMedics, Fluxion Biosciences, Janssen Diagnostics, Adnagen, Advanced Cell Diagnostics, Apocell, Vitatex Inc., Miltenyi Biotech Cynvenio Biosystems, Aviva Biosciences, Biocept Inc., Biofluidica, Creatv Microtech Inc., Ikonisys Inc., Epic Biosciences, Biocep Ltd., Greiner Bio-one GmbH, Sysmex Corporation, and CellTraffix Inc. 

These market entities are involved in collaborations with hospitals and university based research institutes in order to gain access to target population and develop novel technologies for CTC enrichment & detection.

Table of Contents
s

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
Chapter 3. CTC Industry Outlook
3.1. Market Segmentation
3.2. Market Size and Growth Prospects
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. CTC Market Dynamics
3.4. CTC Market Segment Mapping, 2014
3.5. Industry Analysis -Porter's
3.6. CTC Market Competitive Landscape, 2014
3.7. CTC Market PESTEL Analysis
Chapter 4. CTC Technology Outlook
4.1. CTC Enrichment
4.1.1. Market Estimates and Forecasts, 2012 - 2022 (USD Million)
4.1.2. CTC Enrichment Segment Mapping, 2014
4.1.3. Ex-vivo Positive Selection
4.1.3.1. Market Estimates and Forecasts, 2012 - 2022 (USD Million)
4.1.4. In-vivo Positive Selection
4.1.4.1. Market Estimates and Forecasts, 2012 - 2022 (USD Million)
4.1.5. Negative Selection
4.1.5.1. Market Estimates and Forecasts, 2012 - 2022 (USD Million)
4.1.6. Microchips
4.1.6.1. Market Estimates and Forecasts, 2012 - 2022 (USD Million)
4.1.7. Single Spiral Micro Channel
4.1.7.1. Market Estimates and Forecasts, 2012 - 2022 (USD Million)
4.2. CTC Detection
4.2.1. Market Estimates and Forecasts, 2012 - 2022 (USD Million)
4.2.2. CTC Detection Segment Mapping, 2014
4.2.3. Immunocytochemical technologies
4.2.3.1. Market Estimates and Forecasts, 2012 - 2022 (USD Million)
4.2.4. Molecular(RNA) Based Technologies
4.2.4.1. Market Estimates and Forecasts, 2012 - 2022 (USD Million)
4.2.5. Multiphoton Intravital Flow Cytometry
4.2.5.1. Market Estimates and Forecasts, 2012 - 2022 (USD Million)
4.2.6. EPISPOT Functional In-vitro Cell Culture
4.2.6.1. Market Estimates and Forecasts, 2012 - 2022 (USD Million)
4.2.7. Functional In-vitro Cell Invasion Assay
4.2.7.1. Market Estimates and Forecasts, 2012 - 2022 (USD Million)
4.2.8. Xenotransplantation Models
4.2.8.1. Market Estimates and Forecasts, 2012 - 2022 (USD Million)
Chapter 5. CTC Application Outlook
5.1. Tumorigenesis
5.1.1. Market Estimates and Forecasts, 2012 - 2022 (USD Million)
5.2. EMT Biomarkers Development
5.2.1. Market Estimates and Forecasts, 2012 - 2022 (USD Million)
5.3. Cancer Stem Cell Research
5.3.1. Market Estimates and Forecasts, 2012 - 2022(USD Million)
5.4. Other CTC Applications
5.4.1. Others Market Estimates and Forecasts, 2012 - 2022 (USD Million)
Chapter 6. CTC Regional Outlook (Revenue, USD Million, 2012 - 2022)
6.1. North America
6.1.1. North America CTC Market, by Technology, 2012 - 2022 (USD Million)
6.1.1.1. U.S. Market Estimates & Forecast
6.1.1.2. Canada Market Estimates & Forecast
6.1.2. North America CTC Market, by Application, 2012 - 2022 (USD Million)
6.1.2.1. U.S. Market Estimates & Forecast
6.1.2.2. Canada Market Estimates & Forecast
6.2. Europe
6.2.1. Europe CTC Market, by Technology, 2012 - 2022 (USD Million)
6.2.1.1. Germany Market Estimates & Forecast
6.2.1.2. France Market Estimates & Forecast
6.2.1.3. UK Market Estimates & Forecast
6.2.2. Europe CTC Market, by Application, 2012 - 2022 (USD Million)
6.2.2.1. Germany Market Estimates & Forecast
6.2.2.2. France Market Estimates & Forecast
6.2.2.3. UK Market Estimates & Forecast
6.3. Asia Pacific
6.3.1. Asia Pacific CTC Market, by Technology, 2012 - 2022 (USD Million)
6.3.1.1. China Market Estimates & Forecast
6.3.1.2. Japan Market Estimates & Forecast
6.3.2. Asia Pacific CTC Market, by Application, 2012 - 2022 (USD Million)
6.3.2.1. China Market Estimates & Forecast
6.3.2.2. Japan Market Estimates & Forecast
6.4. Latin America
6.4.1. Latin America CTC Market, by Technology, 2012 - 2022 (USD Million)
6.4.1.1. Brazil Market Estimates & Forecast
6.4.2. Latin America Pacific CTC Market, by Application, 2012 - 2022 (USD Million)
6.4.2.1. Brazil Market Estimates & Forecast
6.5. MEA
6.5.1. MEA CTC Market, by Technology, 2012 - 2022 (USD Million)
6.5.1.1. South Africa Market Estimates & Forecast
6.5.2. MEA Pacific CTC Market, by Application, 2012 - 2022 (USD Million)
6.5.2.1. South Africa Market Estimates & Forecast
Chapter 7. Competitive Landscape
7.1. Adnagen AG
7.1.1. Company Overview
7.1.2. Revenue Analysis
7.1.3. Product Benchmarking
7.1.4. Strategic Development
7.2. Advanced Cell Diagnostics
7.2.1. Company Overview
7.2.2. Revenue Analysis
7.2.3. Product Benchmarking
7.2.4. Strategic Development
7.3. Apocell
7.3.1. Company Overview
7.3.2. Revenue Analysis
7.3.3. Product Benchmarking
7.3.4. Strategic Development
7.4. Aviva Biosciences
7.4.1. Company Overview
7.4.2. Revenue Analysis
7.4.3. Product Benchmarking
7.4.4. Strategic Development
7.5. Biocep Ltd.
7.5.1. Company Overview
7.5.2. Revenue Analysis
7.5.3. Product Benchmarking
7.5.4. Strategic Development
7.6. Biocept Inc.
7.6.1. Company Overview
7.6.2. Revenue Analysis
7.6.3. Product Benchmarking
7.6.4. Strategic Development
7.7. Biofluidica
7.7.1. Company Overview
7.7.2. Revenue Analysis
7.7.3. Product Benchmarking
7.7.4. Strategic Development
7.8. Canopus Biosciences
7.8.1. Company Overview
7.8.2. Revenue Analysis
7.8.3. Product Benchmarking
7.8.4. Strategic Development
7.9. CellTraffix Inc.
7.9.1. Company Overview
7.9.2. Revenue Analysis
7.9.3. Product Benchmarking
7.9.4. Strategic Development
7.10. Clearbridge BioMedics
7.10.1. Company Overview
7.10.2. Revenue Analysis
7.10.3. Product Benchmarking
7.10.4. Strategic Development
7.11. Creatv Microtech Inc.
7.11.1. Company Overview
7.11.2. Revenue Analysis
7.11.3. Product Benchmarking
7.11.4. Strategic Development
7.12. Cynvenio Biosystems Inc.
7.12.1. Company Overview
7.12.2. Revenue Analysis
7.12.3. Product Benchmarking
7.12.4. Strategic Development
7.13. Epic Biosciences
7.13.1. Company Overview
7.13.2. Revenue Analysis
7.13.3. Product Benchmarking
7.13.4. Strategic Development
7.14. Fluxion Biosciences.
7.14.1. Company Overview
7.14.2. Revenue Analysis
7.14.3. Product Benchmarking
7.14.4. Strategic Development
7.15. Greiner Bio-One GmbH
7.15.1. Company Overview
7.15.2. Revenue Analysis
7.15.3. Product Benchmarking
7.15.4. Strategic Development
7.16. Ikonisys Inc.
7.16.1. Company Overview
7.16.2. Revenue Analysis
7.16.3. Product Benchmarking
7.16.4. Strategic Development
7.17. IV Diagnostics Inc.
7.17.1. Company Overview
7.17.2. Revenue Analysis
7.17.3. Product Benchmarking
7.17.4. Strategic Development
7.18. Janssen Diagnostics
7.18.1. Company Overview
7.18.2. Revenue Analysis
7.18.3. Product Benchmarking
7.18.4. Strategic Development
7.19. Miltenyi Biotech
7.19.1. Company Overview
7.19.2. Revenue Analysis
7.19.3. Product Benchmarking
7.19.4. Strategic Development
7.20. Nanostring Technologies Inc.
7.20.1. Company Overview
7.20.2. Revenue Analysis
7.20.3. Product Benchmarking
7.20.4. Strategic Development
7.21. Rarecells
7.21.1. Company Overview
7.21.2. Revenue Analysis
7.21.3. Product Benchmarking
7.21.4. Strategic Development
7.22. ScreenCell
7.22.1. Company Overview
7.22.2. Revenue Analysis
7.22.3. Product Benchmarking
7.22.4. Strategic Development
7.23. Silicon Biosystems USA
7.23.1. Company Overview
7.23.2. Revenue Analysis
7.23.3. Product Benchmarking
7.23.4. Strategic Development
7.24. Stem Cell Technologies
7.24.1. Company Overview
7.24.2. Revenue Analysis
7.24.3. Product Benchmarking
7.24.4. Strategic Development
7.25. Sysmex Corporation
7.25.1. Company Overview
7.25.2. Revenue Analysis
7.25.3. Product Benchmarking
7.25.4. Strategic Development
7.26. Vitatex Inc
7.26.1. Company Overview
7.26.2. Revenue Analysis
7.26.3. Product Benchmarking
7.26.4. Strategic Development

List of Tables


1. CTC market - Industry Snapshot & Key Buying Criteria, 2012 - 2022
2. Global CTC market, by technology, 2012 - 2022 (USD Million)
3. Global CTC market, by application, 2012 - 2022 (USD Million)
4. Global CTC market, by region, 2012 - 2022 (USD Million)
5. CTC- Key market driver analysis
6. CTC- Key market restraint analysis
7. North America CTC market, by technology, 2012 - 2022 (USD Million)
8. North America CTC enrichment methods market, by technology, 2012 - 2022 (USD Million)
9. North America CTC detection methods market, by technology, 2012 - 2022 (USD Million)
10. North America CTC market, by application, 2012 - 2022 (USD Million)
11. U.S. CTC market, by technology, 2012 - 2022 (USD Million)
12. U.S. CTC enrichment methods market, by technology, 2012 - 2022 (USD Million)
13. U.S. CTC detection methods market, by technology, 2012 - 2022 (USD Million)
14. U.S. CTC market, by application, 2012 - 2022 (USD Million)
15. Canada CTC market, by technology, 2012 - 2022 (USD Million)
16. Canada CTC enrichment methods market, by technology, 2012 - 2022 (USD Million)
17. Canada CTC detection methods market, by technology, 2012 - 2022 (USD Million)
18. Canada CTC market, by application, 2012 - 2022 (USD Million)
19. Europe CTC market, by technology, 2012 - 2022 (USD Million)
20. Europe CTC enrichment methods market, by technology, 2012 - 2022 (USD Million)
21. Europe CTC detection methods market, by technology, 2012 - 2022 (USD Million)
22. Europe CTC market, by application, 2012 - 2022 (USD Million)
23. Germany CTC market, by technology, 2012 - 2022 (USD Million)
24. Germany CTC enrichment methods market, by technology, 2012 - 2022 (USD Million)
25. Germany CTC detection methods market, by technology, 2012 - 2022 (USD Million)
26. Germany CTC market, by application, 2012 - 2022 (USD Million)
27. UK CTC market, by technology, 2012 - 2022 (USD Million)
28. UK CTC enrichment methods market, by technology, 2012 - 2022 (USD Million)
29. UK CTC detection methods market, by technology, 2012 - 2022 (USD Million)
30. UK CTC market, by application, 2012 - 2022 (USD Million)
31. France CTC market, by technology, 2012 - 2022 (USD Million)
32. France CTC enrichment methods market, by technology, 2012 - 2022 (USD Million)
33. France CTC detection methods market, by technology, 2012 - 2022 (USD Million)
34. France CTC market, by application, 2012 - 2022 (USD Million)
35. Asia Pacific CTC market, by technology, 2012 - 2022 (USD Million)
36. Asia Pacific CTC enrichment methods market, by technology, 2012 - 2022 (USD Million)
37. Asia Pacific CTC detection methods market, by technology, 2012 - 2022 (USD Million)
38. Asia Pacific CTC market, by application, 2012 - 2022 (USD Million)
39. China CTC market, by technology, 2012 - 2022 (USD Million)
40. China CTC enrichment methods market, by technology, 2012 - 2022 (USD Million)
41. China CTC detection methods market, by technology, 2012 - 2022 (USD Million)
42. China CTC market, by application, 2012 - 2022 (USD Million)
43. Japan CTC market, by technology, 2012 - 2022 (USD Million)
44. Japan CTC enrichment methods market, by technology, 2012 - 2022 (USD Million)
45. Japan CTC detection methods market, by technology, 2012 - 2022 (USD Million)
46. Japan CTC market, by application, 2012 - 2022 (USD Million)
47. Latin America CTC market, by technology, 2012 - 2022 (USD Million)
48. Latin America CTC enrichment methods market, by technology, 2012 - 2022 (USD Million)
49. Latin America CTC detection methods market, by technology, 2012 - 2022 (USD Million)
50. Latin America CTC market, by application, 2012 - 2022 (USD Million)
51. Brazil CTC market, by technology, 2012 - 2022 (USD Million)
52. Brazil CTC enrichment methods market, by technology, 2012 - 2022 (USD Million)
53. Brazil CTC detection methods market, by technology, 2012 - 2022 (USD Million)
54. Brazil CTC market, by application, 2012 - 2022 (USD Million)
55. MEA CTC market, by technology, 2012 - 2022 (USD Million)
56. MEA CTC enrichment methods market, by technology, 2012 - 2022 (USD Million)
57. MEA CTC detection methods market, by technology, 2012 - 2022 (USD Million)
58. MEA CTC market, by application, 2012 - 2022 (USD Million)
59. South Africa CTC market, by technology, 2012 - 2022 (USD Million)
60. South Africa CTC enrichment methods market, by technology, 2012 - 2022 (USD Million)
61. South Africa CTC detection methods market, by technology, 2012 - 2022 (USD Million)
62. South Africa CTC market, by application, 2012 - 2022 (USD Million)